Mandate

Vinge advises Lunar in connection with the transfer of all customer relationships within its P2P business to SaveLend

April 11, 2023 Financial Regulatory M&A

Vinge advises Lunar Bank A/S in connection with the transfer of all customer relationships with investors and lenders within its P2P business and related trademark and domain names to SaveLend Group AB’s subsidiary SBL Finans AB (publ).

The transfer includes approximately 17,000 active investors, 7,000 active borrowers and an invested capital of approximately MSEK 450. Lunar has operated its P2P business since 2021. In order to streamline its business, Lunar has actively been looking for a new home for its P2P customers, both investors and borrowers. Through the transaction, all customer relationships will as of closing be taken over and managed through SaveLend Group’s own platform and customer service team. 

Completion is subject to the approval of the Danish Financial Supervisory Authority.

Vinge’s team mainly consisted of Filip Öhrner, Robin Fagerström (M&A) and Caroline Krassén (Financial Services).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025